{
  "id": "5a737b483b9d13c70800000b",
  "type": "list",
  "question": "Which drugs were tested in the KEYNOTE-006 study?",
  "ideal_answer": "KEYNOTE-006 study compared pembrolizumab versus ipilimumab for advanced melanoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27896938",
    "http://www.ncbi.nlm.nih.gov/pubmed/25891173",
    "http://www.ncbi.nlm.nih.gov/pubmed/28987768",
    "http://www.ncbi.nlm.nih.gov/pubmed/28822576",
    "http://www.ncbi.nlm.nih.gov/pubmed/26846323",
    "http://www.ncbi.nlm.nih.gov/pubmed/28964438",
    "http://www.ncbi.nlm.nih.gov/pubmed/28125365"
  ],
  "snippets": [
    {
      "text": "The model used Kaplan-Meier estimates of progression-free survival and overall survival from a recent randomized phase 3 study (KEYNOTE-006) that compared pembrolizumab and ipilimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28125365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Substantiating the results of the interim analyses of KEYNOTE-006, pembrolizumab continued to provide superior overall survival versus ipilimumab, with no difference between pembrolizumab dosing schedules. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pembrolizumab (Keytruda(\u00ae)) is a humanized monoclonal antibody against programmed death receptor-1 (PD-1), a key immunoinhibitory checkpoint protein implicated in down-regulating anti-tumour immune responses. This intravenous drug is indicated for the treatment of advanced (unresectable or metastatic) melanoma, on the basis of its clinical benefit in this setting in the phase I KEYNOTE 001 trial (expansion cohorts) and the phase II and III trials, KEYNOTE 002 and 006.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846323",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp&Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25891173",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The model used Kaplan-Meier estimates of progression-free survival and overall survival from a recent randomized phase 3 study (KEYNOTE-006) that compared pembrolizumab and ipilimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28125365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A cost-effectiveness model was developed to analyze the costs and consequences of treatment with pembrolizumab compared to treatment with ipilimumab in patients with advanced melanoma not previously treated with ipilimumab. The model was parameterized by using data from a head-to-head phase III randomized clinical trial, KEYNOTE-006.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964438",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION Substantiating the results of the interim analyses of KEYNOTE-006, pembrolizumab continued to provide superior overall survival versus ipilimumab, with no difference between pembrolizumab dosing schedules.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The model used Kaplan-Meier estimates of progression-free survival and overall survival from a recent randomized phase 3 study (KEYNOTE-006) that compared pembrolizumab and ipilimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28125365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the trials with active comparator arms, pembrolizumab regimens significantly improved progression-free survival (PFS), overall survival (OS) and overall response rates (ORR) relative to ipilimumab in ipilimumab-na\u00efve patients (KEYNOTE 006), and significantly improved PFS and ORR, but not OS (although OS data are immature), relative to chemotherapy in ipilimumab-refractory patients, who had also received BRAF/MEK inhibitor therapy if BRAF-mutation positive (KEYNOTE 002).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846323",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "pembrolizumab, ipilimumab"
}